Executive Team

Michael L. Babich

President and Chief Executive Officer

Michael L. Babich has served as our President since November 2010 and was appointed as our Chief Executive Officer in March 2011. From March 2007 until November 2010, Mr. Babich served as the Chief Operating Officer and a director of INSYS Pharma, Inc., a wholly-owned subsidiary of our company which is responsible for the initial development of Dronabinol SG Capsule and many of our product candidates, including Subsys and our other dronabinol product candidates. Prior to that, from 2001 to 2007 Mr. Babich worked at EJ Financial Enterprises, Inc., a venture capital firm specializing in early stage and startup investments primarily in the healthcare sector.

During his time at EJ Financial Enterprises, Mr. Babich held various roles and worked on various projects, including private equity transactions, asset management and strategic consulting for both public and private companies. Prior to his work at EJ Financial Enterprises, Mr. Babich worked at the Northern Trust Corporation managing mid- to large-cap portfolios for high net worth individuals. Mr. Babich also has served as a director and in management roles at Alliant Pharmaceuticals, Inc.

Mr. Babich received a B.A. from the University of Illinois at Urbana-Champaign and an MBA from the Kellogg School of Management at Northwestern University.

Larry Dillaha, M.D.

Chief Medical Officer

Larry Dillaha, M.D. has served as our Chief Medical Officer since March 2011. Prior to joining our company, he served as Executive Vice-President and Chief Medical Officer for Shionogi and Co., Ltd. (formerly Sciele Pharma, Inc. and First Horizon Pharmaceutical Corp.). While at Shionogi/Sciele, Dr. Dillaha oversaw the development and successful FDA filings of numerous compounds integral to the success of the company. He has extensive experience interacting with the FDA and designing successful drug development plans.

Prior to serving as an officer of Shionogi/Sciele, Dr. Dillaha served as Medical Director for Sanofi-aventis, a multinational pharmaceutical company, where he was involved in several major clinical studies for the company’s lead compounds. Dr. Dillaha also serves as a member of the board of directors of InVasc Therapeutics, Inc., a pharmaceutical company.

Dr. Dillaha earned his M.D. degree as well as a B.A. in Biology from the University of Tennessee.

Darryl S. Baker

Chief Financial Officer

Darryl S. Baker has served as our Chief Financial Officer since October 2012. From 1997 to 2012, Mr. Baker served as Chief Financial Officer and Corporate Controller for various publicly-traded and entrepreneurial companies, including iGo, a developer of power management solutions and accessories for mobile electronic devices, Integrated Information Systems, a provider of secure integrated information technology solutions, and SkyMall, an integrated specialty retailer. Prior to 1997, Mr. Baker was an audit manager for Ernst & Young LLP.

Mr. Baker has extensive experience in accounting, SEC issues for smaller public companies, merger and acquisition transactions, and small business financing and frequently serves as a panelist and lecturer for the Center for Professional Education on various topics including SEC compliance, share-based compensation, revenue recognition, fair value and lease accounting. Mr. Baker earned his BS in Accountancy from the Marriott School of Management at Brigham Young University and is a Certified Public Accountant in the states of California and Arizona and is also a Chartered Global Management Accountant.